87 results
8-K
EX-99.1
FBRX
Forte Biosciences Inc
18 Mar 24
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
4:18pm
updates on FB-102 over the course of this year.”
2023 Operating Results
Research and development expenses were $21.9 million for the year ended December … share amounts)
Year Ended December 31,
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from
DEFC14A
FBRX
Forte Biosciences Inc
24 Aug 23
Proxy in contested solicitation
6:15am
to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to R … . Prior to that, Dr. Doberstein served as Senior Vice President, R&D and Chief Research and Development Officer at Nektar from November 2017 to October
PREC14A
xqbwc0qr6pus ctb8zp
2 Aug 23
Preliminary proxy with contested solicitation
5:28pm
8-K
EX-99.1
mvkuvgsc0mmpfh2 nj
31 Mar 23
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides
4:06pm
8-K
EX-99.1
e3v obzln9jffrh2r1me
14 Nov 22
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
4:05pm
8-K
7xo6dt
14 Nov 22
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
4:05pm
8-K
EX-99.2
x8sig204
15 Aug 22
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
4:20pm
8-K
EX-99.1
rcxo vs8v914
15 Aug 22
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
4:20pm
424B5
ws2qm0dpl8uq4k1k nrr
12 Aug 22
Prospectus supplement for primary offering
4:46pm
DEFA14A
e0sj8bbleo4imdw
19 May 22
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
7i7j1
16 May 22
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
9:01am